Crossmark

Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment

Crossref DOI link: https://doi.org/10.1007/s10461-022-03749-8

Published Online: 2022-07-01

Published Print: 2023-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Brothers, Sarah https://orcid.org/0000-0002-8454-6240
DiDomizio, Elizabeth

Nichols, Lisa

Brooks, Ralph

Villanueva, Merceditas
Funding

Funding for this research was provided by:

Health Resources and Services Administration (HRSA -17-047)
License Information

Text and Data Mining valid from 2022-07-01

Version of Record valid from 2022-07-01
More Information

Article History

Accepted: 6 June 2022

First Online: 1 July 2022

Declarations

:

: The authors have no conflicts of interest to declare that are relevant to the content of this article.

: This study was approved by the Human Research Ethics committee of Yale University (Ethics Approval Number: 2000022384). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

: Verbal informed consent was obtained prior to the interview from all individual participants included in the study.

: Not applicable.

Document is current

Any future updates will be listed below